Defence Therapeutics: Making a Global Impact

October 26, 2022

Stocks to Invest in: Healthcare

Defence Therapeutics is a Canadian Biotech company developing next generation biopharmaceutical innovations for various immuno-oncology (IO) and infectious diseases (ID) indications.

The company is located in Quebec, and their leadership team brings extensive eperience in the capital markets, finance, biochemistry, pharmacology, biotech, immunology.

Their platform is known as ACCUM, which is suitable to enhance the delivery of proteins, RNA and DNA.

Accum is overcoming problematic cell recycling and rejection patterns, ACCUM™ is the first solution to enable ADCs to control intracellular delivery of chemotherapeutic drugs, resulting in superior pre-clinical anti-tumor activity.

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.


You might also like

Healthcare
Defence Therapeutics: Revolutionizing Immune-Related Therapies with ACCUM Technology

Defence Therapeutics is a Canadian biotech company developing immune-related therapies using their proprietary ACCUM technology.

Healthcare
Investor Alert - Defence Therapeutics: Developing Immune-related Therapies for Cancer Treatment

Defence Therapeutics is a Canadian biotech company developing immune-related therapies for cancer treatment, including cancer vaccines, antibodies, and drug delivery vehicles.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, YouTube and more!